Setmelanotide vs PT-141 (Bremelanotide)

The distinction that mattersBoth melanocortin agonists. Setmelanotide targets MC4R for genetic obesity and is dosed daily; PT-141 targets MC3R/MC4R for sexual desire and is dosed on demand.

	Setmelanotide FDA Approved	PT-141 (Bremelanotide) FDA Approved
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong	5/5 Very strong Evidence rating 5 out of 5: Very strong
Regulatory status	FDA-approved for obesity due to POMC, PCSK1 or LEPR deficiency, and for Bardet-Biedl syndrome	FDA-approved (2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women
Category	Metabolic & Weight	Sexual Health & Melanocortin
Drug class	Melanocortin-4 receptor (MC4R) agonist — cyclic octapeptide	Melanocortin receptor agonist (MC3R/MC4R) — cyclic heptapeptide
Route	Subcutaneous, once daily	Subcutaneous autoinjector, as needed
Half-life	~11 hours	~2.7 hours
Studied in	Pivotal open-label trials in POMC/LEPR deficiency and a randomized trial in Bardet-Biedl syndrome.	RECONNECT phase 3 trials in premenopausal women with HSDD; earlier studies in erectile dysfunction including an intranasal formulation that was discontinued over blood-pressure effects.
Who should avoid it	Patients without a qualifying genetic diagnosis Pregnancy Untreated significant depression (relative)	Uncontrolled hypertension Known cardiovascular disease Pregnancy Postmenopausal women and men (outside approved indication)
Legal status	Prescription drug restricted to labelled genetic indications.	Prescription drug for its labelled indication. "Research grade" PT-141 sold online is unapproved.

Benefits — Setmelanotide

Large weight loss in genetically defined obesity
Most patients with POMC or LEPR deficiency achieved 10% or greater weight loss at one year, in a population previously considered untreatable.
Marked hunger reduction
Patient-reported hyperphagia scores fell substantially, which for these families is often more meaningful than the weight number.
Clear genetic selection criteria
Confirmatory genetic testing identifies responders before treatment, avoiding open-ended trials of therapy.

Benefits — PT-141 (Bremelanotide)

Statistically significant desire improvement
Phase 3 trials showed improvement in validated desire and distress scores versus placebo, sufficient for FDA approval.
On-demand rather than daily dosing
Taken ahead of anticipated activity, unlike flibanserin which requires continuous daily use.
Central mechanism
Addresses desire directly, useful where vascular-acting drugs are irrelevant to the problem.
No alcohol interaction restriction
A practical advantage over flibanserin, which carries alcohol warnings.

Risks & cons — Setmelanotide

Skin hyperpigmentation
Very common, because MC1R cross-activation increases melanin. New or darkening naevi need dermatologic assessment.
Depression and suicidal ideation warning
Labelled warning requiring psychiatric monitoring, particularly in adolescents.
Spontaneous penile erections
A predictable melanocortin class effect; reported in a substantial minority of male patients.
Injection-site reactions and nausea
Common but usually manageable.
No benefit in common polygenic obesity
It is not a general weight-loss drug and should not be sought as one.

Risks & cons — PT-141 (Bremelanotide)

Nausea
The dominant adverse effect — roughly 40% of patients in trials, and about 1 in 8 required an antiemetic.
Transient blood pressure increase
Systolic rises of several mmHg with a compensatory heart-rate decrease. Contraindicated in uncontrolled hypertension or known cardiovascular disease.
Hyperpigmentation with repeated dosing
Focal darkening of the face, gums and breasts occurred in trials, more often with frequent use; may be permanent. Dosing is capped at 8 doses per month partly for this reason.
Modest average effect size
Statistically significant but clinically modest; response rates leave many patients unimproved.
Flushing and injection-site reactions
Common but generally mild.

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.